Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
In the citing paper
“Capsid-specific T cell responses to AAV-based therapies were not predicted from proof-of-concept studies in animal models but were identified in human studies.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
Smith, T. A. G., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., & Kaleko, M. (1993) · Nature Genetics · doi:10.1038/ng1293-397 · Cited by 335
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
Kay, M. A., Rothenberg, S., Landen, C. N., Bellinger, D. A., Leland, F., Toman, C., Finegold, M., Thompson, A. R., Read, M. S., Brinkhous, K. M., et al. (1993) · Science · doi:10.1126/science.8211118 · Cited by 304
Self-citation
Research works printed but not linked: 2
- Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
- Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Cited by
Items 401–429 of 429
Cataldi, M. P. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Cellular Immunity in Recombinant Adeno-Associated Virus Vector Mediated Gene Therapy
Xu, D. (2011) · OhioLink ETD Center (Ohio Library and Information Network)
Genetic manipulation of the pancreas
Ayuso, E., & Bosch, F. (2007)
Liu, X. (1999) · OhioLink ETD Center (Ohio Library and Information Network)
Philpott, J. (2000) · OhioLink ETD Center (Ohio Library and Information Network)
Therapy and mechanism of Mendelian eye diseases
Tsai, Y.-T. (2018) · doi:10.7916/d8k37bhv
In vivo Hepatocyte Genome Manipulation via Intravenous Injection of Genome Editing Components
Nakamura, S., Ando, N., Ishihara, M., & Sato, M. (2020) · OBM Genetics · doi:10.21926/obm.genet.2004119
cGMP Recombinant FIX for IV and Oral Hemophilia B Therapy
Investigator, W. H. V. P., Investigator, A. S. L., Investigator, C. J. L., Investigator, M. M. L., Investigator, M. M. L., Investigator, P. M. L., Nichols, T. C., & Cott, K. E. V. (2005) · Lincoln (University of Nebraska)
Self-citationLuzzatto, L. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.13409045.15186056
Intrinsically Disordered Proteins, Structural and Functional Dynamics
Naureen, I., Saleem, A., Rehman, H. H., farooq, U., Iqbal, I., Sehar, T., & Ali, T. (2022) · Scholars International Journal of Biochemistry · doi:10.36348/sijb.2022.v05i01.002
Ginn, S. L., & Alexander, I. E. (2008) · Wiley eBooks · doi:10.1002/9780471462422.eoct354
Bilirubin Glucuronosyltransferase
Bosma, P. J. (2002) · Wiley eBooks · doi:10.1002/0471203076.emm1126
Teschendorf, C., & Schmiegel, W. (2000) · Springer eBooks · doi:10.1007/978-3-642-57194-7_74
Ginn, S. L., & Alexander, I. E. (2014) · Wiley eBooks · doi:10.1002/9781118445112.stat06926
Ginn, S. L., & Alexander, I. E. (2005) · Wiley eBooks · doi:10.1002/0471667196.ess7172
GENE THERAPY FOR T-CELL IMMUNODEFICIENCIES
Kohn, D. B., Weinberg, K. I., & Parkman, R. (2000) · Radiologic Clinics of North America · doi:10.1016/s0033-8389(22)00188-9
Martiniuk, F. T., Martiniuk, J., Mack, A., & Cheng, S. H. (2025) · DNA and cell biology reports. · doi:10.1089/dcbr.2025.0025
Atlas, D., Buckshaw, E., Hanna, D. B., Lannon, J., Mahmud, A., Mirvis, M., Pham, A. C., Ramnarain, N., Randazzo, P. A., Safferman, M., et al. (2013) · University Libraries (University of Maryland)
Disease gene mapping in border collie dogs
Melville, S. A. (2006) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/15414
SILVERBERG JR, J. (2025) · Institutional Research Information System University of Ferrara (University of Ferrara)
Transcriptional targeting of suicide genes in cancer gene therapy
Katabi, M. M. (1999) · doi:10.82308/32740
Landry, S. (2003) · eScholarship@McGill (McGill) · doi:10.82308/45509
Mecanismos para indução da tolerância imunológica após transferência gênica no fígado do rato gunn
Privato, M. B. (2005) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Cell- and Stage-specific Impact of TNF-alpha Receptor Signaling in Alzheimer's Disease
Montgomery, S. L., & O’Banion, M. K. (2013) · UR Research (University of Rochester)
Grupp, J. (2008) · bonndoc (University of Bonn)
Trieu, Y. (2003) · TSpace (University of Toronto)
Preclinical study of an optimized AAV cancer vaccine in a spontaneous canine model of oral melanoma
Ghersa, F., Yung, C., Molina, E., Kuoch, H., Caine, C., Krotova, K. Y., Borgatti, A., & Aslanidi, G. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201282
Investigating liver tissue dynamics to improve in vivo gene therapy
Starinieri, F. (n.d.) · Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele
Metadata
- Authors
- Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., Read, M. S., Bellinger, D. A., Brinkhous, K. M., & Kay, M. A.
- Affiliations
- University of Washington (US)
- Stanford Medicine (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Medicine
- Published
- 1999-01
- Volume
- 5
- Issue
- 1
- Pages
- 64-70
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/4751
- OpenAlex
- W1588659566
- Cited by
- 409
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 8 · 2012: 12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl001648-50)
- National Heart, Lung, and Blood Institute (HL 53682, R01HL053682, HL-01648)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus vectors, gene therapy, canine model, mouse model, liver gene transfer, coagulation correction, X-linked bleeding disorder, vector toxicity
- MeSH terms
- Dependovirus, Animals, Antibodies, Bleeding Time, Cell Transformation, Viral, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Humans, Liver, Mice, Inbred C57BL, Recombination, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.